ALK and non-small cell lung carcinoma: The positive results of the ALEX study marked the begin of a new era in the treatment of anaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK+ NSCLC) at the end of 2017: the second-generation tyrosine kinase inhibitor (TKI) alectinib could improve both progression-free (PFS) and overall survival (OS) in a head-to-head comparison as first-line therapy vs. the first-generation compound crizotinib, thus irrevocably displacing it as the preferred upfront pharmaceutical [1,2,3].